2007 JASN IMPACT FACTOR 7.111	HOME   AUTHOR INFO   EDITORIAL BOARD   SUBSCRIBE   FEEDBACK   ALERTS   HELP
advanced	CURRENT ISSUE	ARCHIVES	JASN Express	ONLINE SUBMISSION

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Campese, V. M. Articles by Epstein, M. Search for Related Content PubMed PubMed Citation Articles by Campese, V. M. Articles by Epstein, M.

Are 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors Renoprotective?

Vito M. Campese^*, Mitra K. Nadim^* and Murray Epstein

^* Division of Nephrology, Keck School of Medicine, University of Southern California, Los Angeles, California; and Division of Nephrology & Hypertension, University of Miami, Miami, Florida

Address correspondence to: Dr. Vito M. Campese, Department of Medicine, Physiology and Biophysics, Division of Nephrology and Hypertension Center, Keck School of Medicine, University of Southern California, 1200 North State Street, Los Angeles, CA 90033. Phone: 323-226-7337; Fax: 323-226-5390; E-mail: campese{at}usc.edu

Statins reduce serum cholesterol and cardiovascular morbidity and mortality. The mechanisms for these beneficial effects are reviewed. Altered inflammatory responses and improved endothelial function mediated by statins are thought to be partly responsible for the reduction of morbidity and mortality as a result of cardiovascular events. In analogy, whether statins confer similar benefits on the kidney has not been established. This review critically considers the available data whereby dyslipidemia mediates renal dysfunction by modulating the inflammatory response to diverse cytokines. Also reviewed is the emerging database indicating that statins may modulate renal function by altering the response of the kidney to dyslipidemia.

This article has been cited by other articles:

				F. C. Cormack-Aboud, P. T. Brinkkoetter, J. W. Pippin, S. J. Shankland, and R. V. Durvasula Rosuvastatin protects against podocyte apoptosis in vitro Nephrol. Dial. Transplant., September 27, 2008; (2008) gfn528v1. [Abstract] [Full Text] [PDF]

				M.-S. Zhou, I. H. Schuman, E. A. Jaimes, and L. Raij Renoprotection by statins is linked to a decrease in renal oxidative stress, TGF-{beta}, and fibronectin with concomitant increase in nitric oxide bioavailability Am J Physiol Renal Physiol, July 1, 2008; 295(1): F53 - F59. [Abstract] [Full Text] [PDF]

				G. F M Strippoli, S. D Navaneethan, D. W Johnson, V. Perkovic, F. Pellegrini, A. Nicolucci, and J. C Craig Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials BMJ, March 22, 2008; 336(7645): 645 - 651. [Abstract] [Full Text] [PDF]

				B. Najafian, D. B. Franklin, and A. B. Fogo Acute Renal Failure and Myalgia in a Transplant Patient J. Am. Soc. Nephrol., November 1, 2007; 18(11): 2870 - 2874. [Abstract] [Full Text] [PDF]

				L. Romayne Kurukulasuriya, G. Athappan, G. Saab, A. Whaley Connell, and J. R. Sowers Review: HMG CoA reductase inhibitors and renoprotection: the weight of the evidence Therapeutic Advances in Cardiovascular Disease, October 1, 2007; 1(1): 49 - 59. [Abstract] [PDF]

				R. C. Ozsoy, W. A. van der Steeg, J. J. P. Kastelein, L. Arisz, and M. G. Koopman Dyslipidaemia as predictor of progressive renal failure and the impact of treatment with atorvastatin Nephrol. Dial. Transplant., June 1, 2007; 22(6): 1578 - 1586. [Abstract] [Full Text] [PDF]

Copyright © 2008 by the American Society of Nephrology. Online ISSN: 1533-3450 Print ISSN: 1046-6673